The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase
NCT ID: NCT02755337
Last Updated: 2016-04-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
70 participants
OBSERVATIONAL
2016-01-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment
NCT00752076
Detection Cell Free DNA in Lung Cancer Patients
NCT02738593
Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors
NCT02851329
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC
NCT02422628
Novel Detection System for Lung Cancer Curative Effect Monitoring
NCT02666755
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary Objective: To evaluate the subjective response of NSCLC patients harboring a positive EGFR mutation who treated with Gefitinib.
Safety Objective: To evaluate the safety and tolerability of Gefitinib in NSCLC patient harboring a positive EGFR mutation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adenocarcinoma and/or nonadenocarcinoma based on histology examination
* Clinical stadium stage IIIB and IV
* Age 16-70 years old
* Received gefitinib as therapy
* At least completed 2 (two) data sets of RECIST 1.1 evaluations during the study period from January 2013 until July 2015
Exclusion Criteria
16 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Soetomo General Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Laksmi Wulandari, MD, PhD, FCCP
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laksmi Wulandari, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Dr. Soetomo General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Soetomo General Hospital
Surabaya, East Java, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dr. Soetomo General Hospital
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.